Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2023-06-30 Delisting Announcement
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
주권매매거래정지(중요한 영업정지)
Delisting Announcement Classification · 100% confidence The document is a short, formal notice regarding the suspension of stock trading for (주)비보존제약 due to a significant business suspension. It cites specific KOSDAQ market regulations. As it is a regulatory announcement regarding trading status rather than a financial report, proxy, or corporate action, it falls under the general regulatory filing category.
2023-06-30 Korean
주요사항보고서(영업정지)
Regulatory Filings Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korea Exchange regarding the suspension of business operations (영업정지). It details the cessation of a specific business segment, the financial impact, and the rationale behind the decision. Since this is a specific regulatory disclosure regarding corporate operations and does not fit into categories like financial reports, dividends, or management changes, it is classified as a general regulatory filing.
2023-06-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership of Specific Securities by Executives and Major Shareholders'. This is a standard regulatory filing in South Korea (often referred to as a '5% report' or 'insider ownership report') used to disclose changes in shareholdings by major shareholders or executives. This aligns with the 'Major Shareholding Notification' (MRQ) category as it details changes in significant share ownership levels.
2023-06-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including conversion price adjustments and the exercise of call options by major shareholders and related parties. This falls under the category of Major Shareholding Notification.
2023-06-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the shareholding status, changes in ownership, and collateral agreements (pledges) by major shareholders (Vaultea, Inc. and others) in Vivozon Pharmaceutical. This type of filing is a mandatory disclosure to the Financial Services Commission and the Korea Exchange regarding significant ownership stakes and is classified as a Major Shareholding Notification.
2023-06-09 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Vivozon Pharmaceutical' (주식회사 비보존제약) covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial statements, business operations, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.